Fronto-temporal alterations and affect regulation in methamphetamine dependence with and without a history of psychosis

Psychiatry Research - Neuroimaging

Volumn 248, Issue , 2016, Pages 30-38

  Uhlmann, Anne ^a   Fouche, Jean Paul ^a,b   Koen, Nastassja ^a   Meintjes, Ernesta M ^a   Wilson, Don ^a   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Brain imaging; Cortical thickness; Emotion regulation; MRI; Psychostimulant use

Indexed keywords

ADULT; AFFECT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); EMOTION; EMOTIONALITY; FEMALE; FUSIFORM GYRUS; GLOBUS PALLIDUS; HIPPOCAMPUS; HUMAN; INFERIOR FRONTAL GYRUS; INFERIOR TEMPORAL GYRUS; INSULA; MALE; METHAMPHETAMINE ASSOCIATED PSYCHOSIS; METHAMPHETAMINE DEPENDENCE; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; PUTAMEN; THALAMUS; ADOLESCENT; AMPHETAMINE DEPENDENCE; BRAIN CORTEX; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHIATRIC DIAGNOSIS; SELF CONTROL; YOUNG ADULT;

CENTRAL STIMULANT AGENT; METHAMPHETAMINE;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL CORTEX; DIAGNOSIS, DUAL (PSYCHIATRY); EMOTIONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHAMPHETAMINE; PSYCHOTIC DISORDERS; SELF-CONTROL; YOUNG ADULT;

EID: 84957431264     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2016.01.010     Document Type: Article

References (81)

1. Akiyama K., Saito A., Shimoda K. Chronic methamphetamine psychosis after long-term abstinence in Japanese incarcerated patients. Am. J. Addict. 2011, 20:240-249.
2. Aoki Y., Orikabe L., Takayanagi Y., Yahata N., Mozue Y., Sudo Y., Ishii T., Itokawa M. Volume reductions in frontopolar and left perisylvian cortices in methamphetamine induced psychosis. Schizophr. Res. 2013, 147(2):355-361.
3. Asanuma M., Miyazaki I., Higashi Y., Tsuji T., Ogawa N. Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Ann. New. Y. Acad. Sci. 2004, 1025:69-75.
4. Barr A.M., Panenka W.J., MacEwan G.W., Thornton A.E., Lang D.J., Honer W.G., Lecomte T. The need for speed: an update on methamphetamine addiction. J. Psychiatry Neurosci. 2006, 21:301-313.
5. Berman S., O'Neill J., Fears S., Bartzokis G., London E.D. Abuse of amphetamines and structural abnormalities in the brain. Ann. New. Y. Acad. Sci. 2008, 1141:195-220.
6. Braun A.A., Herring N.R., Schaefer T.L., Hemmerle A.M., Dickerson J.W., Seroogy K.B., Vorhees C.V., Williams M.T. Neurotoxic (+)-methamphetamine treatment in rats increases brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) expression in multiple brain regions. Neuroscience 2011, 184:164-171.
7. Burhler M., Mann K. Alcohol and the human brain: a systematic review of different neuroimaging methods. Alcoholism: Clin. Exp. Res. 2011, 35(10):1771-1793.
8. Chang L., Cloak C., Patterson K., Grob C., Miller E.N., Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol. Psychiatry 2005, 57:967-974.
9. Cheetham A., Allen N.B., Yücel M., Lubman D.I. The role of affective dysregulation in drug addiction. Clin. Psychol. Rev. 2010, 30(6):621-634.
10. Churchwell J.C., Carey P.D., Ferrett H.L., Stein D.J., Yurgelun-Todd D.A. Abnormal striatal circuitry and intensified novelty seeking among adolescents that abuse methamphetamine and cannabis. Dev. Neurosci. 2012, 34(4):310-317.
11. Daumann J., Koester P., Becker B., Wagner D., Imperati D., Gouzoulis-Mayfrank E., Tittgemeyer M. Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry. NeuroImage 2011, 54:794-801.
12. Davidson C., Gow A.J., Lee T.H., Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. 2001, 36(1):1-22.
13. Davidson R.J., Irwin W. The functional neuroanatomy of emotion and affective style. Trends Cognit. Sci. 1999, 3(1):11-21.
14. Davidson R.J., Putnam K.M., Larson C.L. Dysfunction in the neural circuitry of emotion regulation: a possible prelude to violence. Science 2000, 289:591-594.
15. Desikan R.S., Segonne F., Fischl B., Quinn B.T., Dickerson B.C., Blacker D., Buckner R.L., Dale A.M., Maguire R.P., Hyman B.T., Albert M.S., Killiany R.J. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 2006, 31:968-980.
16. First, M.B., Gibbon, M., Spitzer, R.L., Williams, J.B.W.. User's Guide for the Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Research Version-(SCID-I for DSM-IV-TR, November 2002 Revision).
17. Fischl B. FreeSurfer. NeuroImage 2012, 62(2):774-781.
18. Fischl B., van der Kouwe A., Destrieux C., Halgren E., Segonne F., Salat D.H., Busa E., Seidman L.J., Goldstein J., Kennedy D., Caviness V., Makris N., Rosen B., Dale A.M. Automatically parcellating the human cerebral cortex. Cereb. Cortex 2004, 14:11-22.
19. Franklin T.R., Wetherill R.R., Jagannathan K., Johnson B., Mumma J., Hager N., Rao H., Childress A.R. The effects of chronic cigarette smoking on gray matter volume: influence of sex. Plos One 2014, 9(8):e104102.
20. Fusar-Poli P., Borgwardt S., Crescini A., Deste G., Kempton M.J., Lawrie S., Mc Guire P., Sacchetti E. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci. Biobehav. Rev. 2011, 35(5):1175-1185.
21. Garver D.L., Holcomb J.A., Christensen J.D. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol. Psychiatry 2005, 58:62-66.
22. Grant K.M., LeVan T.D., Wells S.M., Li M., Stoltenberg S.F., Gendelman H.E., Carlo G., Bevins R.A. Methamphetamine-associated psychosis. J. Neuroimmune Pharmacol. 2012, 7:113-139.
23. Grant P. Letter to the Editor: Haloperidol but not dopamine rapidly induces neuronal death: comments on 'a systematic review of the effects of antipsychotic drugs on brain volume'. Psychol. Med. 2013, 43. 1568-1568.
24. Gratz K.L., Roemer L. Multidimensional assessment of emotion regulation and dsyregulation: development, factor structure, and initial validation of the difficulties in emotion regulation scale. J. Psychopathol. Behav. Assess. 2004, 26:41-54.
25. Haxby J.V., Hoffman E.A., Gobbini M.I. The distributed human neural system for face perception. Trends Cognit. Sci. 2000, 4:223-232.
26. Homer B.D., Solomon T.M., Moeller R.W., Mascia A., DeRaleau L., Halkitis P.N. Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol. Bull. 2008, 134:301-310.
27. 1H-MRS in methamphetamine dependence and methamphetamine induced psychosis. Schizophr. Res. 2014, 153:122-128.
28. Hutton C., Draganski B., Ashburner J., Weiskopf N. A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. Neuroimage 2009, 48(2):371-380.
29. Hyman C., Hofer M., Barde Y.A., Jahasz M., Yancopoulos G.D., Squinto S.P., Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350:230-232.
30. Jernigan T.L., Gamst A.C., Archibald S.L., Fennema-Notestine C., Mindt M.R., Marcotte T.D., Heaton R.K., Ellis R.J., Grant I. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am. J. Psychiatry 2005, 162:1461-1472.
31. Kay S.R., Fiszbein A., Opler L.A. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
32. Kim D.J., Roh S., Kim Y., Yoon S.J., Lee H.K., Han C.S., Kim Y.K. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci. Lett. 2005, 388:112-115.
33. Kim S.J., Lyoo I.K., Hwang J., Chung A., Hoon Sung Y., Kim J., Kwon D.H., Chang K.H., Renshaw P.F. Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers. Int. J. Neuropsychopharmacol. 2006, 9:221-228.
34. Kim Y.T., Kwon D.H., Chang Y. Impairments of facial emotion recognition and theory of mind in methamphetamine abusers. Psychiat Res. 2011, 186:80-84.
35. Koester B., Tittgemeier M., Wagner D., Becker B., Gouzoulis-Mayfrank E., Dauman J. Cortical thinning in amphetamine-type stimulant users. Neuroscience 2012, 221:182-192.
36. Kohn N., Eickhoff S., Scheller M., Laird A., Fox P., Habel U. Neural network of cognitive emotion regulation - an ALE meta-analysis and MACM analysis. NeuroImage 2014, 87:345-355.
37. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
38. Kuperberg G., Heckers S. Schizophrenia and cognitive function. Curr. Opin. Neurobiol. 2000, 10:205-210.
39. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., Goff D., West W.C., Williams S.C., van der Kouwe A.J., Salat D.H., Dale A.M., Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60:878-888.
40. Lapworth K., Dawe S., Davis P., Kavanagh D., Young R., Saunders J. Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. Addict. Behav. 2009, 34(4):380-385.
41. LaVoie M.J., Card J.P., Hastings T.G. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 2004, 187:47-57.
42. Lawyer G., Bjerkan P.S., Hammarberg A., Jayaram-Lindström N., Franck J., Agartz I. Amphetamine dependence and co-morbid alcohol abuse: associations to brain cortical thickness. Biomed. Cent. Pharmacol. 2010, 10:5.
43. Lieberman J.A., Tollefson G.D., Charles C. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62:361-370.
44. London E.D., Kohno M., Morales A.M., Ballard M.E. Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. Brain Res. 2015, 1628(A):174-185.
45. Lorenzetti V., Lubman D.I., Whittle S., Solowij N., Yucel M. Structural MRI findings in long-term cannabis users: what do we know?. Subst. Use Misuse 2010, 45(11):1787-1808.
46. Matsuzaki H., Namikawa K., Kiyama H., Mori N., Sato K. Brain-derived neurotrophic factor rescues neuronal death induced by methamphetamine. Biol. Psychiatry 2004, 55:52-60.
47. Meredith C.W., Jaffe C., Ang-Lee K., Saxon A.J. Implications of chronic methamphetamine use: a literature review. Harv. Rev. Psychiatry 2005, 13:141-154.
48. Morales A.M., Lee B., Hellemann G., O'Neill J., London E.D. Gray-matter volume in methamphetamine dependence: cigarette smoking and changes with abstinence from methamphetamine. Drug. alcohol Depend. 2012, 125(3):230-238.
49. Morris R.W., Sparks A., Mitchell P.B., Weickert C.S., Green M.J. Lack of cortico-limbic coupling in bipolar disorder and schizophrenia during emotion regulation. Transl. Psychiatry 2012, 2:e90.
50. Nakama H., Chang L., Fein G., Shimotsu R., Jiang C.S., Ernst T. Methamphetamine users show greater than normal age-related cortical gray matter loss. Addiction 2011, 106(8):1474-1483.
51. Narr K.L., Bilder R.M., Toga A.W., Woods R.P., Rex D.E., Szeszko P.R., Robinson D., Sevy S., Gunduz-Bruce H., Wang Y.P., DeLuca H., Thompson P.M. Mapping cortical thickness and gray matter concentration in first episode schizophrenia. Cereb. Cortex 2005, 15(6):708-719.
52. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? a systematic and critical review of MRI findings. Psychol. Med. 2009, 39(11):1763-1777.
53. Nesvåg R., Lawyer G., Varnäs K., Fjell A.M., Walhovd K.B., Frigessi A., Jönsson E.G., Agartz I. Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. Schizophr. Res. 2008, 98(1):16-28.
54. 2-terminal protein kinase. J. Neurochem. 2000, 75(6):2327-2334.
55. Nock M.K., Wedig M.M., Holmberg E.B., Hooley J.M. The emotion reactivity scale: development, evaluation, and relation to self-injurious thoughts and behaviors. Behav. Ther. 2008, 39:107-116.
56. Orikabe L., Yamasue H., Inoue H., Takayanagi Y., Mozue Y., Sudo Y., Ishii T., Itokawa M., Suzuki M., Kurachi M., Okazaki Y., Kasai K. Reduced amygdala and hippocampal volumes in patients with methamphetamine psychosis. Schizophr. Res. 2011, 132:183-189.
57. Panenka W.J., Procyshyn R.M., Lecomte T., MacEwan G.W., Flynn S.W., Honer W.G., Barr A.M. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug. Alcohol Depend. 2013, 129(3):167-179.
58. Payer D.E., Lieberman M.D., London E.D. Neural correlates of affect processing and aggression in methamphetamine dependence. Arch. Gen. Psychiat 2011, 68:271-282.
59. Phillips M.L., Drevets W.C., Rauch S.L., Lane R. Neurobiology of emotion perception I: the neural basis of normal emotion perception. Biol. Psychiat 2003, 54:504-514.
60. Pillai A., Terry A.V., Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 2006, 82:95-106.
61. Plüddemann A., Flisher A.J., Mathews C., Parry C.D.H., Lombard C.A. Methamphetamine use, aggressive behaviour and other mental health issues among high-school students in Cape Town, South Africa. Drug. Alcohol Depend. 2010, 109:14-19.
62. Plüddemann A., Dada S., Parry C.D., Kader R., Parker J.S., Temmingh H., van Heerden S., de Clercq C., Lewis I. Monitoring the prevalence of methamphetamine-related presentations at psychiatric hospitals in Cape Town, South Africa. Afr. J. Psychiatry 2013, 16(1):45-49.
63. Pu C., Vorhees C.V. Developmental dissociation of methamphetamine-induced depletion of dopaminergic terminals and astrocyte reaction in rat striatum. Dev. Brain Res. 1993, 72:325-328.
64. Quirk G.J., Beer J.S. Prefrontal involvement in the regulation of emotion: convergence of rat and human studies. Curr. Opin. Neurobiol. 2006, 16(6):723-727.
65. Reiner B.C., Keblesh J.P., Xiong H. Methamphetamine abuse, HIV infection, and neurotoxicity. Int. J. Physiol. Pathophysiol. Pharmacol. 2009, 1(2):162-179.
66. Sabatinelli D., Bradley M.M., Fitzsimmons J.R., Lang P.J. Parallel amygdala and inferotemporal activation reflect emotional intensity and fear relevance. NeuroImage 2005, 24:1265-1270.
67. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann. New. Y. Acad. Sci. 1992, 654:160-170.
68. Scherk H., Falkai P. Effects of antipsychotics on brain structure. Curr. Opin. Psychiatry 2006, 19:145-150.
69. Schwartz D.L., Mitchell A.D., Lahna D.L., Luber H.S., Huckans M.S., Mitchell S.H., Hoffman W.F. Global and local morphometric differences in recently abstinent methamphetamine-dependent individuals. NeuroImage 2010, 50:1392-1401.
70. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., Iwata Y., Tsuchiya K.J., Suda S., Suzuki K., Kawai M., Takebayashi K., Yamamoto S., Matsuzaki H., Ueki T., Mori N., Gold M.S., Cadet J.L. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 2008, 28:5756-5761.
71. Scott J.C., Woods S.P., Matt G.E., Meyer R.A., Heaton R.K., Atkinson J.H., Grant I. Neurocognitive effects of methamphetamine: a critical review and analysis. Neuropsychol. Rev. 2007, 14:275-297.
72. Smieskova R., Fusar-Poli P., Allen P., Bendfeldt K., Stieglitz R.D., Drewe J., Radue E.W., McGuire P.K., Riecher-Rössler A., Borgwardt S.J. The effects of antipsychotics on the brain; what have we learnt from structural imaging of schizophrenia? a systematic review. Curr. Pharm. Des. 2009, 15(22):2535-2549.
73. Stegmayer K., Horn H., Federspiel A., Razavi N., Bracht T., Laimböck K., Strik W., Dierks T., Wiest R., Müller T.J., Walther S. Ventral striatum gray matter density reduction in patients with schizophrenia and psychotic emotional dysregulation. Neuroimage Clin. 2014, 4:232-239.
74. Tanabe J., York P., Krmpotich T., Miller D., Dalwani M., Sakai J.T., Mikulich-Gilbertson S.K., Thompson L., Claus E., Banich M., Rojas D.C. Insula and orbitofrontal cortical morphology in substance dependence is modulated by sex. Am. J. Neuroradiol. 2013, 34(6):1150-1156.
75. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y., Lee J.Y., Toga A.W., Ling W., London E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J. Neurosci. 2004, 24:6028-6036.
76. Ursu S., Kring A.M., Gard M.G., Minzenberg M.J., Yoon J.H., Ragland J.D., Solomon M., Carter C.S. Prefrontal cortical deficits and impaired cognition-emotion interactions in schizophrenia. Am. J. Psychiatry 2011, 168:276-285.
77. van der Kouwe A.J.W., Benner T., Salat D.H., Fischl B. Brain morphometry with multiecho MPRAGE. NeuroImage 2008, 40:559-569.
78. Velakoulis D., Wood S., Wong M., McGorry P., Yung A., Phillips L., Smith D., Brewer W., Proffitt T., Desmond P., Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatry 2006, 63(2):139-149.
79. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157:16-25.
80. Yamamoto B.K., Moszczynska A., Gudelsky G.A. Amphetamine toxicities: classical and emerging mechanisms. Ann. New. Y. Acad. Sci. 2010, 1187:101-121.
81. Zweben J.E., Cohen J.B., Christian D., Galloway G.P., Salinardi M., Parent D., Iguchi M. Psychiatric symptoms in methamphetamine users. Am. J. Addict. 2004, 13(2):181-190.